|
|
|
By Vincenzo Gioia and Remco Jan Geukes Foppen | Managing risks associated with AI hallucinations requires "explainability," a process that identifies patterns or behaviors in AI models that are inconsistent with training data or logical expectations. Regulators are mandating transparency in AI models used for drug testing and development. |
|
|
|
| 3 Things To Know When Using Wearables In Your Study | Article | By Kristen Harnack, Castor | As wearables unleash new possibilities, the industry will need an effective strategy to utilize these useful tools. Consider these tips when incorporating wearables in a clinical study. |
|
|
| Are We Ready For A Unified Clinical Platform? | Webinar | Cognizant | Industry experts share their perspectives on end-to-end clinical development and essential elements of a unified clinical platform, as well as the associated benefits and challenges involved. |
|
|
| The Case For Cognitive Assessments In Phase 1 Clinical Trials | Article | By Helen Brooker and Pascal Goetghebeur, Signant Health | Regulators prioritize patient-reported outcomes. Cognitive assessments in Phase 1 trials detect early drug-related cognitive effects, ensuring safety and efficacy. Examine a proven tool for this. |
|
|
| Key Efficiencies Driven By A CTMS | Article | By Tamas Peterson, Advarra | Is your clinical trial management system being used to the fullest? Review the benefits of centralized data management, real-time tracking, automated workflows, and comprehensive reporting. |
|
|
|
| Information Security Is Vital For Decentralized Trials | Article | By Phillip Winters, MRN - Medical Research Network | Information is the most important currency to any business, and it must be protected from being stolen, forged, or devalued. Learn what is crucial for data protection when running DCTs. |
|
|
.png){kind=logo}
